Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity

Anticancer Research

Volumn 25, Issue 6 A, 2005, Pages 3725-3732

  Kuroki, Masahide ^a   Hachimine, Ken ^a   Huang, Jian ^a   Shibaguchi, Hirotomo ^a   Kinugasa, Tetsushi ^a   Maekawa, Shin Ichi ^a   Kuroki, Motomu ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody based therapy; Carcinoembryonic antigen; Cytotoxic T lymphocytes; Immunotherapy; Natural killer cells; Review; Tumor antigen

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD16 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; CELL RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LIGAND; LYMPHOCYTE SURFACE MARKER; MONOCLONAL ANTIBODY; MUCIN 1; NATURAL KILLER CELL RECEPTOR; PEPTIDE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CELL SURFACE; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DEFENSE MECHANISM; EFFECTOR CELL; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TARGET CELL; TUMOR CELL; TUMOR ESCAPE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; HLA ANTIGENS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 27844583464     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Groen TP: Tumor-associated antigens. In: Tumor Immunology; Mechanisms, Diagnosis, Therapy. Den Otter W and Ruitenberg EJ (eds.). Amsterdam , Elsevier, pp. 13-27, 1987.
2. Kuroki Ma, Ueno A, Matsumoto H, Abe H, Li T, Imakiire T, Yamauchi Y, Uno K, Shirota K, Shibaguchi H and Kuroki Mo: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res 22: 4255-4264, 2002.
3. Gold P and Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 722: 467-481, 1965.
4. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5: 957-972, 1979.
5. Bast RCJ, Feeney M, Lazarus H and Nadler LM: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337, 1981.
6. Wang MC, Valenzuela LA, Murphy GP and Chu TM: Purification of a human prostate specific antigen. Invest Urol 17: 159-163, 1979.
7. Kato H and Torigoe T: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40: 1621-1628, 1977.
8. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5: 957-972, 1979.
9. Pemberton L, Taylor-Papadimitriou J and Gendler SJ: Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout mammals. Biochem Biophys Res Commun 185: 167-75, 1992.
10. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A and Shepard HM: Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci USA 85: 5102-5106, 1988.
11. Bofill M, Janossy G, Janossa M, Burford GD, Seymour GJ, Wernet P and Kelemen E: Human B cell development. II. Subpopulations in the human fetus. J Immunol 134: 1531-1538, 1985.
12. Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D and Brautbar C: Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2(8401): 483-486, 1984.
13. Farag SS, Fehniger TA, Ruggeri L, Velardi A and Caligiuri MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100: 1935-1947, 2002.
14. Algarra I, Cabrera T and Garrido F: The HLA crossroad in tumor immunology. Hum Immunol 61: 65-73, 2000.
15. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F and Garrido F: Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52: 1-9, 2003.
16. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nature Med 10: 909-915, 2004.
17. Kuroki Ma, Shibaguchi H, Imakiire T, Uno K, Shirota K, Higuchi T, Shitama T, Yamada H, Hirose Y, Nagata A and Kuroki Mo: Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res 23: 4377-4381, 2003.
18. Darcy PK, Kershaw MH, Trapani JA and Smyth MJ: Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 28: 1663-1672, 1998.
19. Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM and Finer MH: Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol 161: 375-384, 1998.
20. Yamamoto T, Yoneda K, Osaki T, Yoshimura N and Akagi N: Longer local retention of adoptively transferred T-LAK cells correlates with lesser adhesion molecule expression than NK-LAK cells. Clin Exp Immunol 100: 13-20, 1995.
21. Parmiani G, Rivoltini L, Andreol G and Carrabba M: Cytokines in cancer therapy. Immunol Lett 74: 41-44, 2000.
22. Ribeiro RC, Rill D, Roberson PK, Furman WL, Pratt CB, Brenner M, Crist WM and Pui CH: Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer 72: 623-628, 1993.
23. Roitt I, Brostoff J and Male D: Immunology (ed. 5). London, Mosby International Ltd, 1998.
24. Primus FJ, Sharkey RM, Hansen HJ and Goldenberg DM: Immunoperoxidase detection of carcinoembryonic antigen. Cancer 42: 1540-1545, 1978.
25. Nap M, Mollgard K, Burtin P and Fleuren GJ: Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumor Biol 9: 145-153, 1988.
26. Nouwen EJ, Pollet DE, Eerdekens MW, Hendrix PG, Briers TW and De Broe ME: Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 46: 866-876, 1986.
27. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K and Stanners CP: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334, 1989.
28. Hammarstrom S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81, 1999.
29. Khare PD, Liao S, Kuroki Mo, Hirose Y, Arakawa F, Nakamura K, Tomita Y and Kuroki, Ma: Specificaly targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retrovector displaying single chain variable fragmented (scFv) antibody to CEA and carrying inducible nitric oxide synthase (iNOS) gene. Cancer Res 61: 370-375, 2001.
30. Sell S: Cancer markers of the 1990s. Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers. Clin Lab Med 10: 1-37, 1990.
31. Ikeda S, Kuroki Ma, Haruno M, Oikawa S, Nakazato H, Kosaki G and Matsuoka Y: Epitope mapping of the carcinoembryonic antigen with various related recombinant proteins expressed in Chinese hamster ovary cells and 25 distinct monoclonal antibodies. Mol Immunol 29: 229-240, 1992.
32. Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, Hammarström S, Holmes KV, Karlsson A, Kuroki Mo, Lin SH, Lucka L, Najjar SM, Neumaier M, Obrink B, Shively JE, Skubitz KM, Stanners CP, Thomas P, Thompson JA, Virji M, Vonkleist S, Wagener C, Watt S and Zimmermann W: Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 252: 243-249, 1999.
33. Kuroki Mo, Abe H, Imakiire T, Liao S, Uchida H, Yamauchi Y, Oikawa S and Kuroki Ma: Identification and comparison of residues critical for cell adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J Leukocyte Biol 70: 543-550, 2001.
34. Hammarström S, Shively JE, Paxton RJ, Beatty BG, Larsson Ghosh R, Bormer O, Buchegger F, Mach J-P, Burtin P, Seguin P, Darbouret B, Degorce F, Sertour J, Jolu JP, Fuks A, Kalthoff H, Schmiegel W, Arndt R, Kloppel G, von Kleist S, Grunert F, Schwarz K, Matsuoka Y, Kuroki Ma, Wagener C, Weber T, Yachi A, Imai K, Hishikawa N and Tsujisaki M: Antigenic sites in carcinoembryonic antigen. Cancer Res 49: 4852-4858, 1989.
35. Bjerner J, Lebedin Y, Bellanger L, Kuroki Ma, Shively JE, Varaas T, Nustad K, Hammarström S and Bormer OP: Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 Workshop. Tumor Biol 23: 249-262, 2002.
36. Buchsbaum DJ: Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 55(Suppl): 5729s-5732s, 1995.
37. Ishida I, Tomizuka K, Yoshida H, Tahara T, Takahashi N, Ohguma A, Tanaka S, Umehashi M, Maeda H, Nozaki C, Halk E and Lonberg N: Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 4: 91-102, 2002.
38. Imakiire T, Kuroki Mo, Shibaguchi H, Abe H, Yamauchi Y, Ueno A, Hirose Y, Yamada H, Yamashita Y, Shirakusa T, Ishida I and Kuroki Ma: Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int J Cancer 108: 564-570, 2004.
39. Bolhuis RL, Sturm E and Braakman E: T cell targeting in cancer therapy. Cancer Immunol Immunother 34: 1-8, 1991.
40. Kuwahara M, Kuroki Ma, Arakawa F, Senba T, Matsuoka Y, Hideshima T, Yamashita Y and Kanda H: A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res 16: 2661-2667, 1996.
41. Baba M, Hideshima T, Yamashita Y and Shirakusa T: Potentiation of cytotoxicity against a CEA positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patients. Oncol Rep 5: 1141-1146, 1998.
42. Kufer P, Mack M, Gruber R, Lutterbuse, R, Zettl F and Riethmuller G: Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 45: 193-197, 1997.
43. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, Wolf J, Diehl V, Cochet O, Winter G and Bohlen H: Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 59: 2909-2916, 1999.
44. Asano R, Kudo T, Nishimura, Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K and Kumagai I: Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem (Tokyo) 132: 903-909, 2002.
45. Blanco B, Holliger P, Vile RG and Alvarez-Vallina L: Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 171: 1070-1077, 2003.
46. Penichet ML and Morrison SL: Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248: 91-101, 2001.
47. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E and Primus FJ: Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60: 4475-4484, 2000.
48. Liao S, Khare PD, Arakawa F, Kuroki M, Hirose Y, Fujimura S, Tomita Y and Kuroki Ma: Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anticancer Res 21: 1673-1680, 2001.
49. Kalland T, Dohlsten M, Abrahmsen L, Hedlund G, Bjork P, Lando PA, Sundstedt A, Akerblom E and Lind P: Targeting of superantigens. Cell Biophys 22: 147-64, 1993.
50. Ueno A, Arakawa F, Abe H, Matsumoto H, Kudo T, Asano R, Tsumoto K, Kumagai I, Kuroki M and Kuroki Ma: T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res 22: 769-776, 2002.
51. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F and Kurosawa Y: Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149: 960-968, 1987.
52. Schirrmann T and Pecher G: Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Therapy 9: 390-398, 2002.
53. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH and McArthur JG: Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 6: 412-419, 1999.
54. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ and Darcy PK: Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 769: 5780-5786, 2002.
55. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B and Abken H: Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 767: 6123-6131, 2001.
56. Gilham DE, O'neil A, Hughes C, Guest RD, Kirillova N, Lehane M and Hawkins RE: Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 zeta-based chimeric immune receptors. J Immunother 25: 139-151, 2002.
57. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ and Junghans RP: Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 5: 3928-3941, 1999.
58. Arakawa F, Shibaguchi H, Xu Z and Kuroki Ma: Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-shain anti-CEA activity. Anticancer Res 22: 4285-4290, 2002.
59. Sheen AJ, Irlam J, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE and Gilham DE: Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum 46: 793-804, 2003.
60. Robert B, Guillaume P, Luescher I, Romero P and Mach JP: Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 30: 3165-3170, 2000.
61. Robert B, Guillaume P, Luescher I, Doucey MA, Cerottini JC, Romero P and Mach J-P: Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments. Cancer Immunity 1: 2, 2001.
62. Lev A, Novak H, Segal D and Reiter Y: Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. J Immunol 769: 2988-2996, 2002.
63. Donda A, Cesson V, Mach J-P, Corradin G, Primus FF and Robert B: In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts. Cancer Immunity 5: 11, 2003.
64. Lev A, Noy R, Oved K, Novak H, Segal D, Walden P, Zehn D and Reiter Y: Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci USA 707: 9051-9056, 2004.
65. Segal DM, Dower SK and Titus JA: The role of non-immune IgG in controlling IgG-mediated effector functions. Mol Immunol 20: 1177-1189, 1983.